The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
Open accessAbstract
A tumor-homing peptide, F3, selectively binds to endothelial cells in tumor blood vessels and to tumor cells. Here, we show that the cell surface molecule recognized by F3 is nucleolin. Nucleolin specifically bound to an F3 peptide affinity matrix from extracts of cultured breast carcinoma cells. Antibodies and cell surface biotin labeling revealed nucleolin at the surface of actively growing cells, and these cells bound and internalized fluorescein-conjugated F3 peptide, transporting it into the nucleus. In contrast, nucleolin was exclusively nuclear in serum-starved cells, and F3 did not bind to these cells. The binding and subsequent internalization of F3 were blocked by an antinucleolin antibody. Like the F3 peptide, intravenously injected antinucleolin antibodies selectively accumulated in tumor vessels and in angiogenic vessels of implanted “matrigel” plugs. These results show that cell surface nucleolin is a specific marker of angiogenic endothelial cells within the vasculature. It may be a useful target molecule for diagnostic tests and drug delivery applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Self-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Åkerman, M. E., Chan, W. C. W., Laakkonen, P., Bhatia, S. N., & Ruoslahti, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152463399 · Cited by 1,437
Self-citationTat-mediated delivery of heterologous proteins into cells.
Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B., & Barsoum, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.664 · Cited by 1,225
Major nucleolar proteins shuttle between nucleus and cytoplasm
Borer, R. A., Lehner, C. F., Eppenberger, H. M., & Nigg, E. A. (1989) · Cell · doi:10.1016/0092-8674(89)90241-9 · Cited by 1,114
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004 · cited 1×
“Examples include endothelial cell growth factor receptors and integrins (Eliceiri and Cheresh, 1999; Ferrara and Alitalo, 1999; Hynes, 2002), matrix metalloproteases (Brooks et al.”
BackgroundAminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R., Shapiro, L., Arap, W., & Ruoslahti, E. I. (2000) · PubMed · Cited by 966
Self-citationTumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
Cited by
DAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Targeting of drugs and nanoparticles to tumors
Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910104 · Cited by 829
Self-citationThe Biomedical Use of Silk: Past, Present, Future
Holland, C., Numata, K., Rnjak‐Kovacina, J., & Seib, F. P. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201800465 · Cited by 815
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery
Guo, J., Gao, X., Su, L., Xia, H., Gu, G., Pang, Z., Jiang, X., Yao, L., Chen, J., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.004 · Cited by 566
Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging
Park, J., von Maltzahn, G., Zhang, L., Schwartz, M. P., Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2008) · Advanced Materials · doi:10.1002/adma.200800004 · Cited by 557
Self-citationVascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors
Reddy, G. R., Bhojani, M. S., McConville, P., Moody, J., Moffat, B. A., Hall, D. E., Kim, G., Koo, Y.-E. L., Woolliscroft, M. J., Sugai, J. V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0946 · Cited by 491
Discovery and development of anticancer aptamers
Ireson, C. R., & Kelland, L. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0172 · Cited by 481
Tumor penetrating peptides for improved drug delivery
Ruoslahti, E. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.008 · Cited by 459
Self-citationNanocarriers for drug delivery applications
Chamundeeswari, M., Jeslin, J., & Verma, M. L. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-018-00841-1 · Cited by 444
Durr, E., Yu, J., Krasinska, K. M., Carver, L. A., Yates, J. R., Testa, J. E., Oh, P., & Schnitzer, J. E. (2004) · Nature Biotechnology · doi:10.1038/nbt993 · Cited by 420
Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles
Ruoslahti, E. (2012) · Advanced Materials · doi:10.1002/adma.201200454 · Cited by 419
Self-citationTargeted Quantum Dot Conjugates for siRNA Delivery
Derfus, A. M., Chen, A. A., Min, D.-H., Ruoslahti, E., & Bhatia, S. N. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060367e · Cited by 395
Self-citationSilk-based delivery systems of bioactive molecules
Numata, K., & Kaplan, D. L. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.009 · Cited by 385
Reyes-Reyes, E. M., Teng, Y., & Bates, P. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0920 · Cited by 383
Gold nanoparticles: Emerging paradigm for targeted drug delivery system
Kumar, A., Zhang, X., & Liang, X.-J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.10.002 · Cited by 371
Aptamers in the Therapeutics and Diagnostics Pipelines
Kaur, H., Bruno, J. G., Kumar, A., & Sharma, T. K. (2018) · Theranostics · doi:10.7150/thno.25958 · Cited by 366
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Mitochondrial/Cell-Surface Protein p32/gC1qR as a Molecular Target in Tumor Cells and Tumor Stroma
Fogal, V., Zhang, L., Krajewski, S., & Ruoslahti, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6752 · Cited by 346
Self-citationG-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms
Bates, P. J., Reyes-Reyes, E. M., Malik, M. T., Murphy, E. M., O'Toole, M. G., & Trent, J. O. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.12.015 · Cited by 345
Micellar Hybrid Nanoparticles for Simultaneous Magnetofluorescent Imaging and Drug Delivery
Park, J., von Maltzahn, G., Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200801810 · Cited by 333
Self-citationFogal, V., Richardson, A. D., Karmali, P. P., Scheffler, I. E., Smith, J. W., & Ruoslahti, E. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01101-09 · Cited by 329
Self-citationBrain cancer diagnosis and therapy with nanoplatforms☆
KOO, Y., REDDY, G., BHOJANI, M., SCHNEIDER, R., PHILBERT, M., REHEMTULLA, A., ROSS, B., & KOPELMAN, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.012 · Cited by 326
Chen, D., Yang, D., Dougherty, C. A., Lu, W., Wu, H., He, X., Cai, T., Van Dort, M. E., Ross, B. D., & Hong, H. (2017) · ACS Nano · doi:10.1021/acsnano.7b01530 · Cited by 306
Aptamer-Based Tumor-Targeted Drug Delivery for Photodynamic Therapy
Shieh, Y.-A., Yang, S.-J., Wei, M.-F., & Shieh, M.-J. (2010) · ACS Nano · doi:10.1021/nn901374b · Cited by 299
Systematic Surface Engineering of Magnetic Nanoworms for In vivo Tumor Targeting
Park, J., von Maltzahn, G., Zhang, L., Derfus, A. M., Simberg, D., Harris, T. J., Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2009) · Small · doi:10.1002/smll.200801789 · Cited by 293
Self-citationNanophotosensitizers toward advanced photodynamic therapy of Cancer
Lim, C.-K., Heo, J., Shin, S., Jeong, K., Seo, Y. H., Jang, W.-D., Park, C. R., Park, S. Y., Kim, S., & Kwon, I. C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.09.012 · Cited by 293
RNA-binding protein nucleolin in disease
Abdelmohsen, K., & Gorospe, M. (2012) · RNA Biology · doi:10.4161/rna.19718 · Cited by 272
The roles of nucleolin subcellular localization in cancer
Berger, C. M., Gaume, X., & Bouvet, P. (2015) · Biochimie · doi:10.1016/j.biochi.2015.03.023 · Cited by 267
Design of Nanoparticle-Based Carriers for Targeted Drug Delivery
Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016) · Journal of Nanomaterials · doi:10.1155/2016/1087250 · Cited by 265
Molecular imaging of the tumor microenvironment
Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Shi, H., Huang, Y., Zhou, H., Song, X., Yuan, S., Fu, Y., & Luo, Y. (2007) · Blood · doi:10.1182/blood-2007-01-064428 · Cited by 258
Nanoparticle–aptamer bioconjugates for cancer targeting
Farokhzad, O. C., Karp, J. M., & Langer, R. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.3.311 · Cited by 256
Lopes, R., Shi, K., Fonseca, N. A., Gama, A., Ramalho, J. S., Almeida, L., Moura, V., Simões, S., Tidor, B., & Moreira, J. N. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00972-z · Cited by 13
Tao, Z., Li, Y., Huang, Y., Hu, L., Wang, S., Wan, L., She, T., Shi, Q., Lu, S., Wang, X., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113835 · Cited by 13
Metadata
- Authors
- Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., & Ruoslahti, E.
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2003-11-24
- Volume
- 163
- Issue
- 4
- Pages
- 871-878
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- OpenAlex
- W2130389715
- Cited by
- 497
- References
- 35
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.